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Abstract Currently, there is a lack of international and
national guidelines or consensus documents with specific
recommendations for electrocardiogram (ECG) screening
and monitoring during antidepressant treatment. To make a
proper estimation of the risk of cardiac arrhythmias and
sudden (cardiac) death during antidepressant use, both the
drug and patient-specific factors should be taken into
account; however, solid evidence on how this should be
done in clinical practice is lacking. Available
recommendations on the management of QT(c) prolonga-
tion (with antidepressant treatment) emphasize that special
attention should be given to high-risk patients; however,
clinicians are in need of more concrete suggestions about
how to select patients for ECG screening and monitoring.
Based on a review of the literature, a Dutch multidisci-
plinary expert panel aimed to formulate specific guidelines
to identify patients at risk for cardiac arrhythmias and
sudden death by developing a consensus statement
regarding ECG screening before, and monitoring during,
antidepressant use. We first reviewed the literature to
identify the relative risks of various risk factors on cardiac
arrhythmia and sudden (cardiac) death during antidepres-
sant use. These relative contributions of risk factors could
not be determined since no systematic reviews or meta-
analyses quantitatively addressed this topic. Because
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evidence was insufficient, additional expert opinion was
used to formulate recommendations. This resulted in
readily applicable recommendations for clinical practice
for selection of high-risk patients for ECG screening and
monitoring. ECG screening and monitoring is recom-
mended before and following the start of QTc-prolonging
antidepressants in the presence of vulnerability to QTc
prolongation or two or more risk factors (age[65 years,
female sex, concomitant use of a QTc-prolonging drug or
concomitant use of a drug that influences the metabolism of
a QTc-prolonging drug, cardiac disease, excessive dosing
and specific electrolyte disturbances).
Key Points
Evidence from systematic reviews and meta-
analyses with respect to risk factors for
antidepressant-induced cardiac arrhythmia or sudden
(cardiac) death is insufficient to generate relative
risks for individual risk factors.
We present clinically applicable consensus
guidelines for the selection of high-risk patients for
electrocardiogram (ECG) screening and monitoring
during antidepressant use.
ECG screening and monitoring is recommended
before and following the start of QTc-prolonging
antidepressants in the presence of known
vulnerability to QTc prolongation or two or more
risk factors (age[65 years, female sex, concomitant
use of a QTc-prolonging drug or concomitant use of
a drug that influences the metabolism of a QTc-
prolonging drug, cardiac disease, excessive dosing
and specific electrolyte disturbances).
1 Introduction
The effect of psychotropic drugs on cardiac repolarization
has increasingly gained attention in research and clinical
practice over the last 2 decades. The absolute risk of car-
diac arrhythmia, such as Torsade de Pointes (TdP), is
generally low [14 per 10,000 patients over 1 year (95%
confidence interval 11–17/10,000)], and sudden cardiac
death as a consequence of all cardiac arrhythmias in gen-
eral occurs even more rarely [1]. However, the tragic
anecdotes of physically healthy patients encountering car-
diac arrest and sudden (cardiac) death after the use of
psychotropic drugs have underscored that some of these
drugs may increase the risk of arrhythmias. This proar-
rhythmic effect is often marked by a prolongation of the
QT interval/QTc interval (QT interval corrected for heart
rate) on an electrocardiogram (ECG) [2].
Of the psychotropic drugs, antipsychotics are well
known for their QT(c)-prolonging effects and association
with TdP and sudden cardiac death, although the available
evidence may not support this reputation per se [3]. The
incidence rate of sudden cardiac death in users of
antipsychotics was 2.9 per 1000 patient-years—a signifi-
cantly doubled risk compared with (non-psychiatric) non-
users [3]. Some antidepressants have proven to also pro-
long the QT(c) interval. Although a recent meta-analysis
showed significant QTc prolongation by tricyclic antide-
pressants (TCAs; doxepin, nortriptyline and amitriptyline)
and some selective serotonin reuptake inhibitors (SSRIs;
citalopram, escitalopram and sertraline) relative to placebo
[4], CredibleMeds, the internationally renowned source for
evidence-based classification of drugs according to their
QTc-prolonging abilities, only classifies citalopram and
escitalopram as antidepressant drugs with a known risk of
TdP, and clomipramine, desipramine, imipramine, nor-
triptyline, mirtazapine, trimipramine and venlafaxine as
antidepressants with a possible risk of TdP [5]. Moreover,
the US FDA has issued several drug safety communica-
tions, including for citalopram in 2011 and 2012. The
warnings stated that citalopram use could lead to abnormal
heart rhythms, and prescription doses should not exceed
40 mg/day in adults and 20 mg in patients[65 years of
age [6, 7].
To make a proper estimation of the risk of arrhythmia,
the combination of characteristics of the antidepressant
therapy and patient-specific factors should be taken into
account. A number of risk factors that add to the arrhyth-
mia risk, including non-cardiac risk factors, have been
proposed, including female sex, older age, (ischemic) heart
disease or a history thereof, electrolyte disturbances (in-
cluding hypomagnesemia, hypokalemia and hypocal-
cemia), pharmacokinetic and pharmacodynamic genetic
factors, congenital long QTc syndrome, and a range of
other medical conditions [8–11]. Several studies aimed to
verify and synthesize the available evidence for QTc pro-
longation into a risk score for use in non-psychiatric hos-
pitalized patients [12, 13]. In addition, it has been shown
that the risk for arrhythmia increases with increasing
numbers of such risk factors [8–10]; however, the relative
risks of the individual risk factors for the outcome
arrhythmia are still unclear.
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Apart from the ECG monitoring recommendations in the
Summary of Product Characteristics (SmPC) for individual
QT(c)-prolonging antidepressant drugs, there are no clear
and concrete national or international guidelines on if,
when, and how often an ECG should be performed before
and during treatment with antidepressant drugs. In the
Dutch multidisciplinary guideline for depression, only with
TCA treatment in elderly patients is an ECG recommended
before the start of treatment (although this is to rule out
contraindications such as a right bundle branch block to
assist in drug choice, which is not the focus of this con-
sensus document) and ECG monitoring with nortriptyline
treatment in elderly with cardiac risk [14]. Although some
of the available international depression guidelines do not
mention ECG monitoring with antidepressant treatment
[15, 16], other depression guidelines and some consensus
documents for the management of QT(c) prolongation
emphasize that special attention should be given to ‘high-
risk’ patients in order to prevent unfavorable cardiac out-
comes [8, 10, 17–19]. For example, in a consensus docu-
ment, Dodd and colleagues suggest ECG monitoring
during the use of TCAs [20]. They also recommend con-
sidering ECG monitoring during SSRI and serotonin
noradrenaline reuptake inhibitor (SNRI) treatment in ‘high-
risk’ individuals, although they consider it usually unnec-
essary [20]. However, how ‘high-risk’ must be quantified
in clinical practice remains an enigma that hampers
implementation of such recommendations in clinical
practice.
Therefore, we aimed to answer the following important,
unanswered questions in order to prevent cardiac arrhyth-
mia and sudden (cardiac) death during antidepressant use:
(1) should the ECG be monitored with antidepressant
treatment, and (2) if so, for which patients (with which risk
factors), when, and how often?
2 Methods
2.1 The Multidisciplinary Expert Panel
In 2015, the Dutch Network for Quality Development in
Mental Health Care funded the development of recom-
mendations about the prevention, monitoring, and treat-
ment of side effects of psychotropic drugs. A
multidisciplinary expert panel for antidepressant drugs
addressed the association between the use of antidepres-
sants and proarrhythmic effects and related ECG moni-
toring issues. The expert panel for antidepressants
consisted of four psychiatrists (two being specialized in the
treatment of children/adolescents or elderly patients, one
additionally in training as a clinical pharmacologist), a
general practitioner, an internist clinical pharmacologist, a
nursing specialist, a patient representative, three (hospital)
pharmacists, and a postdoctoral researcher.
2.2 Literature Search
In order to retrieve relevant literature as a base for our
recommendations, two authors (AS and MS) searched for
studies addressing the relative risks of risk factors (such as
older age and female sex) for cardiac arrhythmia and
sudden (cardiac) death, associated with antidepressant use.
We did not use a restriction in the time period of publi-
cation and applied no language restrictions. For practical
reasons and because of time restrictions for the project, we
limited our search to systematic reviews and meta-
analyses.
We conducted a search of MEDLINE using the search
strategy ‘‘Psychotropic Drugs’’[MeSH] AND ((((Arrhyth-
mias, Cardiac[MeSH] OR arrhythmi*[tiab] OR proar-
rhythmi*[tiab] OR long QT[tiab] OR (prolong*[tiab] AND
QT[tiab]) OR torsade de pointes[tiab] OR torsades de
pointes[tiab] OR Death, Sudden, Cardiac[MeSH] OR car-
diac death[tiab] OR cardiac mortality[tiab] OR ‘‘Cardio-
vascular Diseases/mortality’’[MeSH]) AND (drug-
induced[tiab] OR drug effects[sh] OR adverse effects[sh]))
AND (Risk factors[MeSH] OR risk factors[tiab] OR
prognost*[tiab] OR predict*[tiab])) AND (systematic*[-
tiab] OR review*[tiab] OR meta-analysis[tiab] OR Meta-
Analysis[ptyp] OR systematic[sb])). We used the broader
term ‘psychotropic drugs’ instead of antidepressant-speci-
fic search terms because a pilot search showed insufficient
studies on risk factors for cardiac arrhythmia and sudden
(cardiac) death when we used antidepressants in the search.
Bibliographies of retrieved studies were scanned for addi-
tional systematic reviews and meta-analyses. We per-
formed the last update of the search on 14 March 2017.
2.3 Selection Criteria
The study selection was performed independently by two
authors (AS and MS) and discrepancies were resolved
through discussion. We selected systematic reviews and
meta-analyses of studies in (older) adult patients using
psychotropic drugs registered in The Netherlands. Papers
limited to overdose, intoxication, supratherapeutic dosage
or antidepressants as add-on intervention were excluded. In
our selection, we focused on cardiac arrhythmia and sud-
den (cardiac) death as outcomes and excluded publications
solely on QTc interval as a surrogate measure for cardiac
arrhythmia and sudden (cardiac) death. The latter was
applied because QTc intervals are of limited value due to
the use of different formulas to correct for heart rate (e.g.
Bazett or Fridericia) and because the relationship between
drug-induced QTc prolongation and the likelihood of
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arrhythmia appears to be, at best, modest and neither linear
nor straightforward [21, 22]. Eligible studies should report
on the risk for cardiac arrhythmia and sudden (cardiac)
death in association with risk factors [e.g. age, sex, cardiac
disease, electrolyte disturbances, prolonged QT(c) interval
(syndrome), use of QT(c)-prolonging drugs].
2.4 Formulation of Recommendations
In order to formulate recommendations, the multidisci-
plinary expert panel received a summary of extracted data
from selected studies. The odds ratios, relative risks and/or
prevalences of cardiac arrhythmia and sudden (cardiac)
death associated with the investigated risk factors were
presented for each review/meta-analysis. This evidence
served as input for discussion on the indication and timing
for ECG screening and monitoring at treatment initiation
and during use of antidepressants. When consensus was
reached, each recommendation was graded evidence level
1–4 according to the Dutch criteria for evidence-based
guideline development (EBRO), based on the Appraisal of
Guidelines Research and Evaluation (AGREE) Collabora-
tion [23–25].
3 Results of the Literature Research
We retrieved 100 publications of potential systematic
reviews and/or meta-analyses (see electronic supplemen-
tary material). Seven titles and abstracts appeared to match
our inclusion criteria; all seven studies were in English.
Based on their full-text, four publications met our selection
criteria [26–29]. The major reasons for exclusion of pub-
lications were failure to meet our population criterion, no
investigation of risk factors, or solely outcomes other than
cardiac arrhythmia and sudden (cardiac) death.
In a systematic review of TdP cases, Meyer-Massetti
et al. investigated the prevalences of a predefined set of risk
factors (age, sex, dose, electrolyte imbalance, cardiac dis-
ease, concomitant proarrhythmic drugs and other drugs
influencing cardiac function and baseline QTc) in 54
patients with intravenous administration of the antipsy-
chotic haloperidol [27]. Vieweg et al. provided prevalences
of various risk factors in only a small number of TdP cases
(n = 4) associated with the antipsychotic risperidone [28].
Because of the low number of cases and the focus on
antipsychotics, the results of these studies were not gen-
eralizable to patients using antidepressants and these two
systematic reviews were therefore excluded.
Zeltser et al. performed a systematic review of TdP
cases and described the prevalence of six risk factors for
arrhythmia in 249 cases of TdP induced by non-cardiac
drugs [29]. In brief, 70 of these cases (28.1%) were caused
by psychotropic drugs, mainly, but not exclusively, by
antipsychotics (not further specified). Of the psychotropic
drug-induced TdP cases, 71.4% were female, 44.7% used
additional drugs that caused drug interactions (i.e. impairs
the metabolism of QT-prolonging drugs or concomitant use
of two or more QT-prolonging drugs), 43.1% had existing
cardiac disease, 27% used an excessive dose (leading to
drug toxicity but excluding cases of suicidal overdose),
17.9% had hypokalemia, and 17.1% had a vulnerability to
QT prolongation (familial history of long QT syndrome,
history of drug-induced TdP, prolonged QT interval before
drug administration). Cases using psychotropic drugs had,
on average, 2.2 risk factors. No odds ratios for the different
risk factors were given.
A study by A˚stro¨m-Lilja et al. investigated the preva-
lence of a small set of risk factors for arrhythmia in drug-
induced TdP [26]. Since Zeltser et al. did not assess age as
a risk factor, the study by A˚stro¨m-Lilja et al. was consid-
ered of substantial added value for the expert panel, despite
the fact that it was not a systematic review or meta-anal-
ysis. This series of 88 cases was based on data from the
Swedish pharmacovigilance database, which was not
restricted to psychotropic drugs [8/88 (9%) used antide-
pressants]. The age of the TdP cases ranged from 15 to
90 years, with the median age being 74 years. Seventy-two
percent of the TdP cases were over 65 years of age.
Existing heart disease, female sex, and hypokalemia were
present in 90, 70, and 12% of cases, respectively, while two
or more established risk factors were present in 85% of
cases (75/88).
4 Considerations of the Expert Panel
In order to translate the available evidence to recommen-
dations for daily clinical practice, we addresses several
issues.
First, the expert panel concluded that the relative con-
tributions of risk factors to cardiac arrhythmias and sudden
(cardiac) death during antidepressant use could not be
determined since no systematic reviews or meta-analyses
addressed this topic specifically.
Second, the absence of a reference group (e.g. drug-free
TdP cases or patients using psychotropic drugs who did not
develop TdP) in the included reports hampered us to put
the prevalences of risk factors into perspective and/or
calculate odds ratios or relative risks. Therefore, it is
impossible to draw firm conclusions on the relative
importance of certain factors or the definition of a high-risk
population for ECG screening and monitoring.
Third, we took the average time to steady state into
account when drafting the advice about the timing of the
follow-up ECG after reaching the target dose of treatment
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with a QTc-prolonging antidepressant. Time to steady state
is four to five times the half-life of the drug, which is
approximately 1 week for antidepressant drugs.
Fourth, the expert panel would like to point out that the
current literature is inconclusive regarding the intraindi-
vidual circadian variation in the length of the QTc interval,
which may range from\10 ms to up to 75–100 ms
[21, 30, 31]. It is therefore preferable to register ECG
recordings at fixed time points during the day in order to
avoid bias in the change between two subsequent ECGs as
a result of circadian variation.
Fifth, because threshold values for a prolonged QTc
interval, such as those of the AHA/ACCF/HRS, are the
result of consensus, the expert panel suggested to consider
a similar threshold value for women and men
(i.e.[450 ms, instead of[450 ms for men and[460 ms
for women [32]), which will reduce complexity for clinical
practice. This is supported by the consideration that women
are at increased risk for QTc prolongation and TdP; low-
ering the threshold for a prolonged QTc interval
to[450 ms in women also, will result in earlier identifi-
cation than with[460 ms [33].
Last, the expert panel noted that because of the actions
of sex hormones on the QTc interval, the difference
between women and men in the prolonged QTc-interval
risk disappears during menopause [34, 35].
5 Recommendations
Based on the limited literature results and the consensus
reached by our expert panel, we formulated the following
recommendations, all graded 4—expert opinion (Fig. 1)
[23–25].
• ECG screening and monitoring is recommended for
antidepressants with known or possible risk of TdP
according to CredibleMeds (citalopram, clomipramine,
desipramine, escitalopram, imipramine, mirtazapine,
nortriptyline, trimipramine and venlafaxine) [5]) if the
patient
1. is having a known risk of QTc prolongation:
– known prolonged QTc interval;
– history of TdP;
– family history of long QTc syndrome or sudden
cardiac death; and choosing an antidepressant
without QTc-prolonging ability is not possible;
Remark: If the risk of QTc prolongation cannot
be determined, it can be considered absent for
decision-making purposes.
or
2. has two or more of the risk factors listed below
(based on the two reviews from the literature
search discussed above [26, 29]):
– age over 65 years;
– female sex;
– concomitant use of a QTc-prolonging drug
(list of drugs with a known risk of TdP
according to CredibleMeds [5]) or concomi-
tant use of a drug that influences the
metabolism of the antidepressant with known
or possible risk of TdP (i.e. citalopram,
clomipramine, desipramine, escitalopram, imi-
pramine, mirtazapine, nortriptyline, trim-
ipramine and venlafaxine [5]);
– cardiac disease (myocardial infarction, heart
failure, valvulopathy, cardiomyopathy);
– excessive dosing (higher than the highest dose
according to the SmPC, or standard dose with
a relevant kidney or liver problem);
– specific electrolyte disturbances (hypocal-
cemia, hypokalemia, hypomagnesemia)
[26, 29].
Additional remark: In case of a strong suspi-
cion of electrolyte disturbances, e.g. with
alcoholism, anorexia nervosa, diarrhea, the
use of loop diuretics, etc., the calcium, potas-
sium and magnesium serum level should be
quantified.
• Paroxetine, duloxetine and fluoxetine do not affect the
QTc interval in comparison with placebo, while
fluvoxamine shortens the QTc interval compared with
placebo [4]. For other antidepressants, evidence for
determining their QTc-prolonging ability is currently
insufficient.
• In general, it is unnecessary to make an ECG prior to
starting any antidepressant if the patient is not at risk of
QTc prolongation, and all of the abovementioned risk
factors for cardiac arrhythmia or conduction disorders
are absent.
• ECG screening and monitoring should consist of an
ECG before treatment initiation and 1 week after
reaching the target dose of a the QTc-prolonging
antidepressant (i.e. when steady state has been
reached).
• In case the ECG shows a QTc interval of 450 ms or
above, it is advisable to consult a cardiologist.
Remark: although we focus on the QTc interval in this
consensus document, the PQ and QRS intervals may
also be relevant during psychotropic drug use.
• If needed, for example in acute situations or highly
severe mentally ill cases, the treating physician can
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deviate from the recommended ECG at treatment
initiation.
6 Discussion
In this Dutch consensus document on ECG screening and
monitoring in patients using antidepressants, no need for
ECG screening and monitoring is recommended in patients
without QTc-prolongation vulnerability and other risk
factors for cardiac arrhythmia during antidepressant ther-
apy. ECG screening and monitoring is recommended
before and following the start of antidepressants with
known or possible risk of TdP (i.e. citalopram, clomipra-
mine, desipramine, escitalopram, imipramine, mirtazapine,
nortriptyline, trimipramine and venlafaxine [5]) in the
presence of vulnerability to QTc prolongation or two or
more risk factors (age[65 years, female sex, concomitant
use of a QTc-prolonging drug or concomitant use of a drug
that influences the metabolism of the QTc-prolonging
antidepressant, cardiac disease, excessive dosing and
specific electrolyte disturbances).
Some authors, guidelines, and drug labels state that all
patients receiving QTc-prolonging psychotropic
medication should be monitored, but most experts and
authors of previous reviews emphasize that ECG screening
and monitoring is only necessary in high-risk patients
[20, 22, 36]. Current guidelines do not provide uniform
recommendations with respect to ECG screening and
monitoring in patients using antidepressants. Unfortu-
nately, there is a lack of evidence that ECG screening and
monitoring indeed can prevent cases of arrhythmia or
sudden cardiac death. For this, the ‘number needed to
ECG’ (NNE) would be an interesting number to indicate
the number of patients who should be monitored (with
consecutive ECGs) to prevent one additional death or
adverse event due to QTc prolongation. Given the rising
costs of (mental) health, the apparent pressure to increase
productivity, and high administrative workload, it would
also be appropriate to perform a proper health economical
cost–benefit assessment before issuing general recom-
mendations on ECG screening and monitoring. An opti-
mized balance between costs and yield of ECG screening
and monitoring to detect aberrances would support clini-
cians in their treatment decisions, while unnecessary ECGs
could be eliminated as much as possible.
Because of a relative lack of systematic reviews and
meta-analyses that compare risk factors (despite a number
Fig. 1 Decision tree for ECG
monitoring with antidepressant
treatment. QTc QT interval
corrected for heart rate, ECG
electrocardiogram, TdP
Torsades de Pointes. aBased on
CredibleMeds.org [5], which
represents available and
evolving evidence that is
constantly re-evaluated when
new evidence becomes
available. bIf the risk of QTc
prolongation cannot be
determined, it can be considered
absent for decision-making
purposes. cIn case of a strong
suspicion of electrolyte
disturbances, e.g. with
alcoholism, anorexia nervosa,
diarrhea, use of loop diuretics,
etc., the calcium, potassium and
magnesium serum level should
be quantified
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of studies on risk scores for QTc prolongation), the relative
risks of risk factors for cardiac arrhythmia and sudden
(cardiac) death cannot be established/quantified, which
hampers a better determination of a ‘high-risk’ population.
Therefore, we decided to consider the various risk factors
that were put forward in two earlier reviews of TdP cases
[26, 29]. The contribution of these risk factors to cardiac
arrhythmia and sudden (cardiac) death have not yet been
quantified. However, the results of our literature study are
corroborated by a recent systematic review by Vandael
et al. of large randomized controlled trials and observa-
tional studies that assessed the level of evidence for several
factors to increase the risk of QTc prolongation in a general
population [37]. Although strong evidence was found for a
few risk factors (including hypokalemia and use of drugs
with known risk of TdP as listed by CredibleMeds [5]),
little or no evidence was found for many other risk factors
[37].
Based on the identified risk factors, Vandael et al. sub-
sequently aimed at developing a risk score to identify
patients at low/high risk for QTc prolongation in an
observational study in hospital patients with a first pre-
scription for haloperidol or a QTc-prolonging antibiotic or
antimicotic [38]. The RISQ-PATH index, using more and
some other risk factors than we mention in this paper, was
able to exclude low-risk patients from further ECG follow-
up when starting QTc-prolonging drugs [high sensitivity
(96.2%)], but also resulted in many false positives [low
specificity (32.9%)] [38]. Because the aim of a risk score
would be to safely exclude patients with low risk from the
total population, this tool seems a promising instrument.
The RISQ-PATH index is similar to our recommendations
for ECG screening and monitoring, except that it addi-
tionally contains a weighing of risk factors based on the
level of evidence—not relative risk—found in their sys-
tematic review. Instead of a risk score, we chose the
dichotomous cut-off of two risk factors as a threshold,
based on the evidence of a higher risk of cardiac arrhyth-
mia outcomes with an increasing number of risk factors,
the average number of risk factors found in the two reviews
from our literature study, the general low absolute risk of
our primary outcomes, and approximation of the same high
sensitivity (i.e. yield of ‘high risk’ cases for cardiac
arrhythmia and/or sudden [cardiac] death vs. costs and
logistics of obtaining ECGs in mental health). Further
research is warranted to quantify the relative risks of each
risk factor and the sensitivity/specificity of a risk score in
people prescribed an antidepressant before implementation
of such a weighted risk index in clinical practice. To obtain
efficacy and (cost-)effectiveness data, ideally a randomized
controlled trial is performed to assign patients to be mon-
itored according to their risk score versus treatment as
usual. This would also enable to determine an NNE to
guide future ECG screening and monitoring guidelines.
However, given the low prevalence of QTc prolongation
and outcomes such as cardiac arrhythmia and sudden death,
performing such an RCT requires large numbers of patients
and resources. Therefore a non-randomized approach as
used by Vandael et al. might be most feasible [38].
For implementation, the counting of risk factors to
determine the need for ECG screening and monitoring
would ideally be incorporated in automated clinical deci-
sion support systems that alert prescribers to obtain ECG
screening and monitoring [39]. The combination of infor-
mation from electronic medical records and an electronic
prescribing system would be supportive in preventing
undesirable outcomes of QTc-prolonging drugs and
increased efficacy of ECG screening and monitoring in
specifically high-risk patients [39].
6.1 Strength and Limitations
The strengths of this paper are the clear recommendations
to select ‘high-risk patients’ for ECG screening and mon-
itoring when prescribing a QTc-prolonging antidepressant,
which are easily applicable in clinical practice. However,
some critical issues must be addressed.
The first limitation of our work is the restriction of our
search to systematic reviews and meta-analyses, which
provided a summary of available case-series but did not
exclude the possibility that reports such as additional case-
series or cohort studies might have been missed. Further-
more, we could only identify papers on patients using
psychotropic drugs in general, without a focus on antide-
pressants. We loosened our restriction to include reports on
antidepressants only after our pilot search showed insuffi-
cient studies when we used ‘antidepressants’ as a search
term. Given our restriction of systematic reviews and meta-
analyses, we think this was the best compromise to retrieve
reviews on patients using antidepressants and risk factors
for cardiac arrhythmia. From four studies initially selected,
only two studies were informative as they included a larger
number of patients also using antidepressants. One of these
was not a systematic review, but was still considered rel-
evant in the absence of additional adequate evidence from
systematic reviews and meta-analyses. Our recommenda-
tions are based on the currently limited available literature
and almost entirely on expert opinion (specific for antide-
pressants) to make them readily applicable in clinical
practice.
Second, risk factors for unfavorable cardiac (arrhyth-
mia) outcomes may be generalizable across populations
using psychotropic and other drugs. If so, a broader review
of studies in patients using non-psychotropic drugs might
have revealed more information, e.g. Vandael et al. [37].
We suggest to evaluate and amend our recommendations
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after new relevant studies have been released, with addi-
tional practice-based experience following implementation
in clinical practice.
Third, we did not include a recommendation on the need
for periodic follow-up (e.g. yearly) after the baseline and
follow-up ECG during antidepressant use. Because evi-
dence on the timing of cardiac arrhythmia and sudden
(cardiac) death relative to the start of antidepressant ther-
apy is scarce, and existence of risk factors may vary with
time, it cannot be expected that a normal ECG after
treatment initiation will indefinitely predict a low risk of
later cardiac arrhythmia outcomes. Therefore, it might be
necessary to repeat ECG screening and monitoring over
time, for which additional recommendations must be for-
mulated when more data are available.
Fourth, the evidence for the QTc-prolonging abilities of
psychotropic drugs is scarce, with inconsistent results. For
sertraline, for example, results on QTc prolongation are
contradictory [40, 41]. The initial classification based on a
recent comparative systematic review and meta-analysis
[4] was carefully re-evaluated. Despite this systematic
review, and in the absence of more specific evidence for
fatal cardiac events for the remaining antidepressants on
the list from this review, we decided to follow the Credi-
bleMeds classification for our recommendations. Together
with this choice, we would like to emphasize again that our
recommendations are not final and may change when
additional evidence appears.
Finally, ECG screening and monitoring recommenda-
tions should be actively and adequately implemented.
Previous research has shown that the introduction of new
guidelines, consensus statements, or (national) quality
improvement programs alone has been minimally effective
in improving screening and monitoring rates [42–45].
Specifically, compliance with these recommendations for
the risk management of QTc prolongation by antidepres-
sants may be poor [46–48].
7 Conclusions
We present specific consensus recommendations for ECG
screening and monitoring in patients using antidepressants.
Although these recommendations are based on limited
evidence in the currently scarcely available literature, the
elaboration of the available evidence in combination with
clinical expertise and the multidisciplinary consensus pro-
cess resulted in readily applicable recommendations,
which, as a next step, need to be empirically validated.
Future research should evaluate these recommendations,
ideally in an RCT comparing their implementation with
care as usual, combined with a health technology assess-
ment, to assess the NNE and cost–benefit ratio. The
recommendations should thereafter be evaluated and
amended if necessary.
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